PARIS & ALAMEDA, Calif.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, and Ipsen (Euronext:FR0010259150;IPN) today announced that they have entered into a research collaboration to develop biomarker and pharmacogenomic tests for growth failure patients. The initial phase of the collaboration will focus on the discovery and characterization of genetic markers relating to this disease. Assuming the first phase of this collaboration is completed successfully, a key aim thereafter will be to develop diagnostic predictors for use in Ipsen’s clinical trials, which would potentially form the basis for commercial companion diagnostic tests for Ipsen’s short stature therapies. Celera will receive an undisclosed payment for the initial phase of this multi-year collaboration, and any future payment will depend on success of the initial phase.
